



From microbes to One Health



**Drug discovery and Drug  
development  
in the field of infectious diseases**

# Vibiosphen's Team



**Maxime FONTANIÉ, MBA**  
Founder and CEO



**Patricia MARTIN, PhD**  
CSO



**Christophe FREMEZ, MSc**  
Head of Laboratory



**Alexandre LAURENT, MSc**  
Pharmacologist



**Robin DUMAS, MSc**  
Business Development



**Célia LECACHEUX, MSc**  
Pharmacologist



# Vibiosphen's Overview

## CRO-services

Pre-clinical models  
TPP definition





❖ *in vitro*



❖ *in vivo*

## Our customers



# Vibiosphen's Overview

## CRO-services

Pre-clinical models  
TPP definition



❖ *in vitro*

❖ Organoids



❖ *in vivo*

## R&D programs

# Vibiosphen's Overview

## CRO-services

Pre-clinical models  
TPP definition



❖ *in vitro*

❖ Organoids



❖ *in vivo*

## R&D programs

Antimicrobial resistance



❖ Polypeptoids

**bpi**france



❖ Horizon Europe Framework Programme



Funded by  
the European Union



IN-ARMOR

# Vibiosphen's Offer

## In vitro services



**Minimum Inhibitory  
Concentration**

---

**Minimum Bactericidal  
Concentration**

---

**Time Kill Curve**

---

**Intracellular bacterial  
quantification**

---

**Extracellular vesicles  
production**

---

**Anti biofilm activity**

---

**Genome editing**

---

**Mechanism of action**

---

**Quantification  
resistance development**

---

**Cytotoxicity**

---

# Vibiosphen's Offer

In vivo services



## Mouse models of infectious diseases

Gastro intestinal

Septicemia

Urinary tract

Respiratory tract

Skin

Thigh

Custom

### Routes of administration

- ❖ Intravenous
- ❖ *per os*
- ❖ Subcutaneous
- ❖ Intraperitoneal
- ❖ Intranasal
- ❖ Inhalation

### End points

- ❖ Clinical signs score
- ❖ Bodyweight
- ❖ Survival
- ❖ Bacterial / viral / fungal load
- ❖ Cytokine / chemokine
- ❖ Histopathological analysis